Skip to main content


'How are these results even possible?': Inside Rep. Chris Collins’ painful biotech education

By Stat News  
   August 09, 2018

It was June 22, 2017, and Innate Immunotherapeutics, an Australian biotech company in which he had heavily invested, was in a crisis. The company’s in-development drug, meant to treat multiple sclerosis, turned out to be no better than placebo in a large clinical trial. The study results were confidential, emailed only to Innate’s board of directors, of which Collins was a member.

Full story

Get the latest on healthcare leadership in your inbox.